Bio Path Holdings Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $13.45 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Bio Path Holdings Inc had its IPO on 2008-03-04 under the ticker symbol BPTH.
The company operates in the Healthcare sector and Biotechnology industry. Bio Path Holdings Inc has a staff strength of 10 employees.
Shares of Bio Path Holdings Inc opened at $1.71 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $1.45 - $1.73, and closed at $1.59.
This is a -5.83% slip from the previous day's closing price.
A total volume of 90,381 shares were traded at the close of the day’s session.
In the last one week, shares of Bio Path Holdings Inc have slipped by -5.83%.
Bio Path Holdings Inc's Key Ratios
Bio Path Holdings Inc has a market cap of $13.45 million, indicating a price to book ratio of 0.7618 and a price to sales ratio of 0.
In the last 12-months Bio Path Holdings Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15746000. The EBITDA ratio measures Bio Path Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bio Path Holdings Inc’s operating margin was 0% while its return on assets stood at -56.26% with a return of equity of -100.45%.
In Q1, Bio Path Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Bio Path Holdings Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bio Path Holdings Inc’s profitability.
Bio Path Holdings Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0769. Its price to sales ratio in the trailing 12-months stood at 0.
Bio Path Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.10 million
- Total Liabilities
- $1.91 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Bio Path Holdings Inc ended 2023 with $11.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.10 million while shareholder equity stood at $9.11 million.
Bio Path Holdings Inc ended 2023 with $0 in deferred long-term liabilities, $1.91 million in other current liabilities, 8000.00 in common stock, $-96802000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.73 million and cash and short-term investments were $6.73 million. The company’s total short-term debt was $110,000 while long-term debt stood at $0.
Bio Path Holdings Inc’s total current assets stands at $10.79 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $827000.00 and inventory worth $0.
In 2023, Bio Path Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Bio Path Holdings Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Bio Path Holdings Inc stock is currently trading at $1.59 per share. It touched a 52-week high of $4.48 and a 52-week low of $4.48. Analysts tracking the stock have a 12-month average target price of $13.
Its 50-day moving average was $1.5 and 200-day moving average was $2.15 The short ratio stood at 3.19 indicating a short percent outstanding of 0%.
Around 42.7% of the company’s stock are held by insiders while 812.2% are held by institutions.
Frequently Asked Questions About Bio Path Holdings Inc
Similar Industry Stocks (Biotechnology)
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.